Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2014

Open Access 01-04-2014 | Research Article

Cognitive memory screening and referral program in community pharmacies in the United States

Authors: Nathaniel M. Rickles, Jann B. Skelton, Jennifer Davis, Jennifer Hopson

Published in: International Journal of Clinical Pharmacy | Issue 2/2014

Login to get access

Abstract

Introduction 12 chain community pharmacy sites located in two geographic areas with the United States implemented easy-to-administer memory screening assessments for patients with risk factors of cognitive memory decline and referred at-risk patients to their physicians. Aim of the study To evaluate the impact of a pharmacy-based cognitive memory screening and referral program, measure patient satisfaction with these advanced clinical services, and assess willingness to pay for cognitive memory screening services. Setting 12 chain pharmacy sites located in two geographic areas—ten Fred Meyer Pharmacies located in the Portland, Oregon area and two Kerr Drug Pharmacies located in North Carolina. Method Pharmacists were educated on Alzheimer’s disease, trained on how to provide cognitive memory screening exams, and equipped with screening and documentation tools. Following each screening, pharmacist provided education and counseling to the patients and referred at-risk patients to physicians for follow-up as appropriate. Main outcome measures Results of screenings; satisfaction of patients; willingness to pay. Results Pharmacists delivered cognitive memory assessments to 161 patients from June to November 2008. 44.1 % of patients experienced at least one cognitive deficiency that required referral to a physician based on the screening conducted. The cognitive memory screening and referral program was highly regarded by patients who completed the satisfaction survey, with 98.4 % of respondents indicating that they were either very satisfied or satisfied with the program. Conclusion Cognitive memory screening can be easily incorporated into clinical service offerings in community pharmacy practice and provides a valuable opportunity to identify patients at-risk and refer them to a physician for appropriate testing and diagnosis.
Literature
3.
go back to reference Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8(2). Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8(2).
6.
go back to reference Hersberger KE, Renggli VP, Nirkko AC, Mathis J, et al. Screening for sleep disorders in community pharmacies: evaluation of a campaign in Switzerland. J Clin Pharm Ther (England). 2006;31:35–41.CrossRef Hersberger KE, Renggli VP, Nirkko AC, Mathis J, et al. Screening for sleep disorders in community pharmacies: evaluation of a campaign in Switzerland. J Clin Pharm Ther (England). 2006;31:35–41.CrossRef
7.
go back to reference Pongwecharak J, Treeranurat T. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci. 2010;32:329–33.PubMedCrossRef Pongwecharak J, Treeranurat T. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci. 2010;32:329–33.PubMedCrossRef
8.
go back to reference Fuller L, Conrad WF, Heaton PC, Panos R, Frede SM, et al. Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting. J Am Pharm Assoc. 2012;52:E59.CrossRef Fuller L, Conrad WF, Heaton PC, Panos R, Frede SM, et al. Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting. J Am Pharm Assoc. 2012;52:E59.CrossRef
9.
go back to reference Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc. 2008;48:379.CrossRef Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc. 2008;48:379.CrossRef
10.
go back to reference Liu Y, McDonough RP, Carruthers KM, Doucette WR. Identifying patients at risk of cardiovascular disease: a pharmacist-managed screening event for union workers and their dependents. J Am Pharm Assoc. 2009;49(4):549–53.CrossRef Liu Y, McDonough RP, Carruthers KM, Doucette WR. Identifying patients at risk of cardiovascular disease: a pharmacist-managed screening event for union workers and their dependents. J Am Pharm Assoc. 2009;49(4):549–53.CrossRef
11.
go back to reference Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacists. J Am Pharm Assoc. 2008;48(3):379–87.CrossRef Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacists. J Am Pharm Assoc. 2008;48(3):379–87.CrossRef
12.
go back to reference Knight DE, Draeger RW, Heaton PC, Patel NC. Pharmacist screening for depression among patients with diabetes in an urban primary care setting. J Am Pharm Assoc. 2008;48(4):518–21.CrossRef Knight DE, Draeger RW, Heaton PC, Patel NC. Pharmacist screening for depression among patients with diabetes in an urban primary care setting. J Am Pharm Assoc. 2008;48(4):518–21.CrossRef
13.
go back to reference Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383–91.CrossRef Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383–91.CrossRef
14.
go back to reference Park K, Hong WH, Kye SY, Jung E, et al. Community-based intervention to promote breast cancer awareness and screening: the Korean experience. BMC Public Health. 2011;11:468.PubMedCentralPubMedCrossRef Park K, Hong WH, Kye SY, Jung E, et al. Community-based intervention to promote breast cancer awareness and screening: the Korean experience. BMC Public Health. 2011;11:468.PubMedCentralPubMedCrossRef
15.
go back to reference Hendrie HC, Albert MS, Butters MA, Gao S, Knopman DS, Launer LJ, et al. The NIH cognitive and emotional health project: report of the Critical Evaluation Study Committee. Alzheimers Dement. 2006;2:12–32.PubMedCrossRef Hendrie HC, Albert MS, Butters MA, Gao S, Knopman DS, Launer LJ, et al. The NIH cognitive and emotional health project: report of the Critical Evaluation Study Committee. Alzheimers Dement. 2006;2:12–32.PubMedCrossRef
16.
go back to reference Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol. 2005;62:1556–60.PubMedCrossRef Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol. 2005;62:1556–60.PubMedCrossRef
18.
go back to reference Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057–64.PubMedCrossRef Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057–64.PubMedCrossRef
19.
go back to reference Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M, Brown T, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol. 2008;64:698–706.PubMedCentralPubMedCrossRef Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M, Brown T, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol. 2008;64:698–706.PubMedCentralPubMedCrossRef
20.
go back to reference Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Dis. 2009;28:75–80.CrossRef Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Dis. 2009;28:75–80.CrossRef
21.
go back to reference Tsivgoulis G, Alexandrov AV, Wadley VG, Unverzagt FW, Go RCP, Moy CS, et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology. 2009;73:589–95.PubMedCentralPubMedCrossRef Tsivgoulis G, Alexandrov AV, Wadley VG, Unverzagt FW, Go RCP, Moy CS, et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology. 2009;73:589–95.PubMedCentralPubMedCrossRef
22.
go back to reference Pendlebury ST, Rothwell PM. Prevalence, incidence and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Neurology; Published online, 24 Sept 2009. www.thelancet.com/neurology. Pendlebury ST, Rothwell PM. Prevalence, incidence and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Neurology; Published online, 24 Sept 2009. www.​thelancet.​com/​neurology.
25.
go back to reference Hill J, McVay JM, Walter-Ginzburg A, Mills CS, Lewis J, Lewis BE, et al. Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the Medicare population. Dis Manag. 2005;8:223–34.PubMedCrossRef Hill J, McVay JM, Walter-Ginzburg A, Mills CS, Lewis J, Lewis BE, et al. Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the Medicare population. Dis Manag. 2005;8:223–34.PubMedCrossRef
26.
go back to reference Dudkiewicz M, Gold S, Monette J, Le Cruguel J, Bergman H. The clock drawing test for the identification of responders to donepezil. Geriatrics Today. 2002;5:17–20. Dudkiewicz M, Gold S, Monette J, Le Cruguel J, Bergman H. The clock drawing test for the identification of responders to donepezil. Geriatrics Today. 2002;5:17–20.
27.
go back to reference Adapted from Duff Canning SJ. c. Neurology. 2004;62:556–562. Adapted from Duff Canning SJ. c. Neurology. 2004;62:556–562.
28.
go back to reference Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021–7.PubMedCrossRef Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021–7.PubMedCrossRef
30.
go back to reference Skelton J. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease: APhA foundation coordinating council to improve collaboration in supporting patients with Alzheimer’s disease. J Am Pharm Assoc. 2008;48:715–21.CrossRef Skelton J. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease: APhA foundation coordinating council to improve collaboration in supporting patients with Alzheimer’s disease. J Am Pharm Assoc. 2008;48:715–21.CrossRef
Metadata
Title
Cognitive memory screening and referral program in community pharmacies in the United States
Authors
Nathaniel M. Rickles
Jann B. Skelton
Jennifer Davis
Jennifer Hopson
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9904-7

Other articles of this Issue 2/2014

International Journal of Clinical Pharmacy 2/2014 Go to the issue

Editorial

Editorial

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.